Compare PHIO & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHIO | AQMS |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 12.8M |
| IPO Year | 2011 | 2015 |
| Metric | PHIO | AQMS |
|---|---|---|
| Price | $1.25 | $3.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.67 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 362.9K | 30.0K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $550.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.34 |
| 52 Week High | $4.19 | $39.37 |
| Indicator | PHIO | AQMS |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 28.60 |
| Support Level | $1.11 | $3.48 |
| Resistance Level | $1.43 | $4.47 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 52.27 | 4.79 |
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.